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Abstract 
A novel photoreactive analog of cholesterol, 3~-(4-azido-3-[125I]iodosalicylic)-cholest-5-ene ([125I]azido-cholesterol), was
used to label both native acetylcholine receptor (AChR)-rich membranes from Torpedo ealiforniea nd affinity-purified 
Torpedo AChRs reconstituted into lipid vesicles. In both cases all four AChR subunits incorporated [125I]azido-cholesterol 
on an equal molar basis and neither the pattern nor the extent of labeling was affected by the presence of the agonist 
carbamylcholine. Labeled regions in each of the AChR subunits were initially mapped by Staphylococcus aureus V8 protease 
digestion to large fragments which contain the AChR transmembrane segments. Sites of [125I]azido-cholesterol incorporation 
were further mapped by exhaustive tryptic digestion of the V8 protease subunit fragments t~V8-20 (t~Ser-173-Glu-338), txV8- 
10 (aAsn-339-Gly-439), and yV8-14 (yLeu-373-Pro-489). The digests were separated by reverse-phase high-performance 
liquid chromatography and labeled peptides identified by amino-terminal sequence analysis. [125I]Azido-cholesterol labeling 
was localized to peptides that contain almost exclusively the ix-M4, t~-M1 and y-M4 membrane spanning segments. These 
results establish that the binding domain for cholesterol is at the lipid-protein interface of the AChR. © 1998 Elsevier 
Science B.V. All rights reserved. 
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I. Introduction 
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ene; [125I]TID, 3-trifluoromethyl-3-(m[lZSI]iodophenyl) diazirine; 
MOPS, 4-morpholinopropanesulfonic acid; SDS-PAGE, sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis; HPLC, high- 
performance liquid chromatography; TFA, trifluoroacetic acid; 
PTH, phenylthiohydantoin 
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The nicotinic acetylcholine receptor (AChR) iso- 
lated from the electroplacque tissue of the marine 
elasmobranch Torpedo californica is a ligand acti- 
vated cation-specific on channel. The 290 kDa mem- 
brane-imbedded pentamer consists of four unique 
subunits, with a stoichiometry of 0t2~78 (for recent 
reviews, see [1,2]). Similar hydropathy profiles and 
considerable sequence homology among the AChR 
subunits serve as the basis for a predicted folding 
topology consisting of four hydrophobic membrane 
spanning ~-helical segments referred to as M1, M2, 
M3 and M4 [3,4]. Substantial experimental evidence 
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supports the pentameric subunit arrangement [5] and 
the M I-M4 folding of the lipid imbedded regions of 
AChR subunits (reviewed in [6]). 
The binding of acetylcholine to sites on the extra- 
cellular domains of the AChR leads to the transient 
opening of a cation-selective ion channel. In the con- 
tinued presence of agonist, the AChR isomerizes to a 
non-conducting, 'desensitized' conformation. Studies 
involving reconstituting purified AChRs into mem- 
branes of defined lipid composition have shown 
that these agonist-induced conformational transitions 
are highly sensitive to the presence of both cholester- 
ol and negatively charged phospholipids [7-10]. The 
use of a variety of spin-labeled lipids has established 
that in accordance with the abundance of cholesterol 
and negatively charged phospholipids in native-re- 
ceptor rich membranes [11,12] these lipids preferen- 
tially interact with the AChR [13-15]. The use of a 
brominated steroid analog in fluorescence quenching 
studies revealed the presence of two different lipid 
binding domains for the AChR [16]; annular sites 
(approximately 45per AChR) which bind both sterol 
and phospholipids and non-annular sites (5-10 sites 
per AChR) which have a 20-fold higher affinity for 
cholesterol. Photoaffinity labeling studies with both 
anionic lipid [17,18] and cholesterol [19,20] analogs 
have further demonstrated a direct interaction of 
these lipids with the AChR. 
The presence of cholesterol has been shown to be 
required for AChR function and a direct specific 
interaction with the receptor has been well docu- 
mented. However, identification of the region(s) in 
the AChR primary structure which contribute to 
the formation of the binding site for cholesterol is 
an important step in obtaining a more complete 
understanding of the role of this lipid in regulating 
AChR structure and function. Here, we provide the 
first evidence of this type by mapping the labeling of 
a photoactivatable cholesterol analog, 3~-(4-azido-3- 
[125I]iodosalicylic)-cholest-5-ene ([125I]azido-choles- 
terol), to the membrane imbedded regions of the 
Torpedo californica AChR. We further provide a 
model of cholesterol action that involves cholesterol 
binding to the interfaces of the lipid-exposed trans- 
membrane segments and by facilitating the subtle 
movements of these domains helping to mediate the 
conformational transitions of the AChR. 
2. Materials and methods 
2.1. Materials 
3c~-(4-Azido-3-[125 I]-iodosalicylic)-cholest-5-ene 
([125I]azido-cholesterol) was prepared by coupling 
3~-aminocholest-5-ene a d4-azido salicylic acid us- 
ing dicyclohexylcarbodiimide, followed by chlor- 
amine T iodination and purification by reverse-phase 
thin-layer chromatography (TLC) [21]. [125I]Azido- 
cholesterol was stored in methanol (,~ 10 Ci/mmol, 
70 ~tCi/ml) at 4°C in the dark. Staphylococcus aureus 
V8 protease was obtained from ICN Biochemicals 
and L-l-tosylamido-2-phenylethyl chloromethyl ke- 
tone (TPCK)-treated trypsin from Worthington Bio- 
chemical. Genapol C-100 (10% w/v) was purchased 
from Calbiochem and sodium cholate from Sigma. 
Asolectin (a crude soybean lipid extract) came from 
Avanti Polar Lipids. 
2.2. AChR-rich membranes 
AChR-rich membranes were isolated from the 
electric organ of Torpedo californica (Aquatic Re- 
search Consultants, San Pedro, CA) according to 
the procedure of Sobel et al. [22], with the modifica- 
tions described previously [23]. The final membrane 
suspensions in 36% sucrose/0.02% NaN3 were stored 
at -80°C. 
2.3. Affinity column purification and reconstitution of 
AChR membranes 
The Torpedo AChR was isolated from detergent 
(cholate) extracts of crude AChR membranes by af- 
finity chromatography in the presence of asolectin 
lipids. Affinity column purification was performed 
using an acetylcholine affinity matrix according to 
the procedure of Ellena et al. [14] with several mod- 
ifications according to the methods outlined in Blan- 
ton and Wang [17]. Briefly, the affinity column ma- 
trix was prepared by coupling cystamine to Affi-gel 
10 (Bio-Rad), reduction with dithiothreitol and final 
modification with bromoacetylcholine bromide. Af- 
finity-purified AChRs were reconstituted with asolec- 
tin at a lipid protein ratio of 800:1 on a mole per 
mole basis and stored at -80°C. 
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2.4. [125I]Azido-cholesterol labeling of  A ChR 
membranes 
To introduce the photoaffinity probe into AChR- 
rich membranes, typically 20 ~tCi (,-~ 1.25 nmol) of 
[125I]azido-cholesterol (methanolic stock solution) 
was dried on the inside of a 10 x 75 mm glass test 
tube with a stream of nitrogen. AChR-rich mem- 
branes (4 mg/ml) in vesicle dialysis buffer (VDB, 
100 mM NaC1, 0.1 mM EDTA, 0.02% NAN3, 
10 mM MOPS pH 7.5) were solubilized with sodium 
cholate at a final concentration of 1% (2 mg/ml pro- 
tein) at 4°C for 1 h (constant stirring). Insoluble 
material was removed by centrifugation at 
39000 ×g for 1 h at 4°C. The solubilized material 
(supernatant) was added to the test tube containing 
a dried layer of [125I]azido-cholesterol (final concen- 
tration ,~ 2.5 gM) and mixed thoroughly. Following 
a 30 min incubation, the solution was divided into 
two aliquots and carbamylcholine (250 gM) added to 
one sample. Following a 1 h incubation the mem- 
brane suspensions were irradiated at 365 nm (Spec- 
troline EN-280L) for 7 min at a distance of < 1 cm. 
All operations, unless specified otherwise, were per- 
formed under reduced lighting conditions and at 
room temperature. Photolyzed material was then 
solubilized in electrophoresis sample buffer and sub- 
jected to SDS-PAGE. 
An alternate method was used to incorporate 
[125I]azido-cholesterol into affinity-purified AChRs 
that have reconstituted into lipid (asolectin) vesicles. 
Asolectin (1 mg in dichloromethane) was dried onto 
the surface of a glass test tube with a stream of nitro- 
gen. To this was added either 20 gCi (analytical la- 
beling) or 100 gCi (preparative labeling) of 
[125I]azido-cholesterol and the organic solvent re- 
moved under a stream of nitrogen. VDB buffer was 
then added, the solution layered with nitrogen, and 
the tube sealed. The solution was vortexed for 15 min 
followed by 60 min of gentle sonication. Affinity pu- 
rified reconstituted AChRs (0.2 mg for analytical and 
1.6 mg for preparative labelings) were added to the 
tube containing [125I]azido-cholesterol. The test tube 
was then sealed in the presence of nitrogen and the 
membrane suspension incubated overnight at 5°C. 
Following overnight incubation, carbamylcholine 
(250 I.tM) was added to appropriate samples and al- 
lowed to equilibrate for 1 h. The samples were irra- 
diated as described above, the membranes pelleted 
(39 000 × g for 1 h), solubilized in electrophoresis 
sample buffer and subjected to SDS-PAGE. 
2.5. SDS-PA GE 
SDS-PAGE was performed according to the meth- 
od of Laemmli [24] with analytical (1.0 mm thick) 
and preparative (1.5 mm) separating els comprised 
of 8% polyacrylamide/0.33% bis-acrylamide. Follow- 
ing electrophoresis, AChR subunits were visualized 
by staining with Coomassie blue R-250 (0.25% (w/v) 
in 45% methanol, 10% acetic acid, 45% dH20) and 
destaining (25% methanol, 10% acetic acid, 65% 
dH20). Stained gels were soaked in distilled water 
overnight and the AChR ~, [3, Y, and 8 bands for 
each labeling condition ( - /+ carbamylcholine) were 
excised and transferred to either a 1.0 or 1.5 mm 
(preparative) thick 15% acrylamide mapping gel 
[25,23]. For analytical abelings, each gel slice was 
overlaid with a solution containing S. aureus V8 pro- 
tease (6 ~tg) and electrophoresed at 50 V constant 
voltage for ,~ 3 h and then at 5 mA constant current 
overnight. After Coomassie blue R-250 staining (2 h) 
and destaining (3-4 h), analytical gels were dried and 
exposed to Kodak X-OMAT film with an intensify- 
ing screen at -80°C. Preparative 8% acrylamide gels 
(1.5 mm thick) were soaked in distilled water over- 
night and the a- and y-subunits excised as an approx- 
imately ,~ 14 cm strip. The strips were transferred to 
individual 15% acrylamide mapping els and overlaid 
with 200 ~tg V8 protease. Following electrophoresis 
and staining (same as analytical gel conditions), the 
subunit fragment bands ~V8-20 (~Ser-173-Glu-338), 
~V8-10 (~Asn-339-Gly-437), and yV8-14 (yLeu-373- 
Pro-489) were excised and the polypeptides eluted 
into 15 ml of Elution buffer (0.1 M NHaHCO3, 
0.1% (w/v) SDS, 1% 13-mercaptoethanol, pH 7.8) 
for 4 days at room temperature with gentle mixing 
[26,27]. The gel suspensions were then filtered 
through Whatman no. 1 paper and concentrated us- 
ing a Centriprep-10 (Amicon). Excess SDS was re- 
moved by acetone precipitation (85% acetone at 
-20°C for ,~ 18 h). 
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2.6. Isolation of [l:5I]azido-cholesterol labeled 
fragments 
For digestion with trypsin, acetone precipitated V8 
protease subunit fragments, t~V8-20, ~V8-10, and 
yV8-14 were resuspended in approximately 300 ~tl 
of 0.1 M NHaHCO3, 0.02% (w/v) SDS, 0.5% Gena- 
pol C-100, pH 7.8 (1-2 mg/ml protein). Trypsin was 
added at a 100% (w/w) enzyme to substrate ratio and 
the digestion allowed to proceed 4 days at room 
temperature. The digests were then separated by re- 
verse-phase HPLC using a Brownlee Aquapore C4 
column (100×2.1 mm) with solvent A (0.08% TFA 
in water), solvent B (0.05% TFA in 60% acetonitrile/ 
40% 2-propanol). A non-linear elution gradient was 
employed (25-100% solvent B in 80 rain) and the 
elution of peptides was monitored by the absorbance 
at 210 nm. Collected fractions were counted for ra- 
dioactivity in a Packard Cobra II Gamma Counter 
and the peak protein/radioactivity-containing frac-
tions were pooled, dried by vacuum centrifugation, 
and resuspended in 20 p,1 of 0.1 M NH4HCO3, 0.1% 
(w/v) SDS, pH 7.8 for protein sequence analysis. 
2.7. Sequence analysis 
Amino terminal sequence analysis was performed 
on a Beckman Instruments (Porton) 20/20 automated 
protein sequencer using gas phase cycles (Texas Tech 
Biotechnology Core Facility). Peptide aliquots (20 
~tl) were immobilized on chemically modified glass 
fiber disks (Beckman Instruments), which were used 
to improve the sequencing yields of hydrophobic 
peptides, and subjected to 10 sequencing cycles. 
The a-M4 peptide, from HPLC purified tryptic di- 
gest of cxV8-10, was radiosequenced on an Applied 
Biosystems model 477A protein sequencer using gas 
phase cycles (in the laboratory of Dr. Jonathan B. 
Cohen, Department of Neurobiology, Harvard Med- 
ical School). Approximately 30% of the release PTH- 
amino acids were separated by an on-line Model 
120A PTH-amino acid analyzer, and approximately 
60% was collected for determination f released L25I 
by y-counting of each sample for 45 min. Initial yield 
(Io) and repetitive yield (R) were calculated by non- 
linear least-squares regression of the observed release 
(M) for each cycle (n): M = IoR n (PTH-derivatives of 
Ser, Thr, Cys, and His were omitted from the fit). 
3. Results 
3.1. Characterization of [l:5I]azido-cholesterol 
labeling of A ChR subunits 
Initial attempts to introduce the cholesterol photo- 
affinity analog [125I]azido-cholesterol (Fig. 1) into 
AChR-rich membranes by addition of an aliquot of 
a methanolic stock solution proved unsatisfactory. 
With a 2 h incubation less than 25% of the 
[125I]azido-cholesterol probe remained associated 
with the AChR-rich membranes following irradiation 
and centrifugation. Subsequent experiments revealed 
that the labeling efficiency was greatly improved by 
incubating probe that has been dried against the 
walls of a glass test tube with detergent (cholate)- 
solubilized AChR-rich membranes. Previous studies 
have shown that cholate solubilized AChRs retain 
their ability to undergo agonist-induced conforma- 
tional transitions and in the absence of agonist he 
receptor emains in the resting state ([28]; M. Blan- 
ton, unpublished ata). Following irradiation, cho- 
late-solubilized AChR-rich membrane polypeptides 
were resolved by SDS-PAGE. The autoradiograph 
of an 8% polyacrylamide slab gel (Fig. 2) shows there 
is significant incorporation of [125I]azido-cholesterol 
into each of the AChR subunits. In addition, there is 
substantial labeling of the cx-subunit of the Na/K- 
ATPase (C~yK, --~95 kDa) and the CLC-0 chloride 
channel (,~ 89 kDa). Addition of the agonist carba- 
mylcholine (Fig. 2, + lane) had no effect on either 
the pattern of incorporation i to individual AChR 
subunits or the overall labeling pattern of AChR- 
rich membrane polypeptides. Based upon y-counting 
of excised gel bands, [J25I]azido-cholesterol in- 
corporates into each of the AChR subunits on an 
equal molar basis. In the absence of agonist the 
labeling stoichiometry is: (1.03):(0.95):(1):(0.85); 
OH 
Fig. 1. Chemical structure of [l:5I]azido-cholesterol. 
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Following incubation with cholinergic ligands, irra- 
diation and centrifugation, greater than 80% of the 
[12SI]azido-cholesterol probe remained associated 
with the membrane pellet. The labeling of AChR 
subunits with [125I]azido-cholesterol was confirmed 
by autoradiographic analysis of dried 8% acrylamide 
SDS-PAGE gels. As with the labeling of cholate- 
solubilized AChR-rich membranes, each of the 
AChR subunits incorporated [125I]azido-cholesterol 
on a equal molar basis and neither the pattern nor 
the extent of subunit labeling was affected by the 
presence of carbamylcholine. 
Fig. 2. Photoincorporation f [125I]azido-cholesterol int  deter- 
gent (sodium cholate) solubilized AChRs in the absence and 
presence of carbamylcholine. Detergent (sodium cholate)-solubi- 
lized AChRs were equilibrated (1 h incubation) with [125I]azido- 
cholesterol in the absence ( -  lane) and in the presence (+ lane) 
of 250 gM carbamylcholine and irradiated at 365 nm (Spectro- 
line EN-280L) for 7 min (at a distance of < 1 cm). Polypepti- 
des were resolved by SDS-PAGE (1.0 mm thick, 8% polyacryl- 
amide gel), visualized by Coomassie blue R-250 staining and 
subjected to autoradiography (3 day exposure with intensifying 
screen). Labeled lipid and free photolysis products were electro- 
phoresed from the gel with the tracking dye. The migration of 
individual AChR subunits is indicated on the left. Significant 
[125I]azido-cholesterol incorporation is also evident in the s-sub- 
unit of the Na/K-ATPase (CtNK, ~ 95 kDa) and in the CLC-0 
chloride channel (,~ 90 kDa). 
and (0.9 5) :(0.90) :(1) :(0.89) in the presence of  agonist 
(ot:~:7:6, n = 3). 
A second method was used to introduce 
125 [ I]azido-cholesterol into afffinity-purified AChR 
lipid reconstituted vesicles. [125I]azido-cholesterol 
containing liposomes were formed by drying asolec- 
tin lipids on the surface of a thick walled glass tube 
followed by a dried layer of [125I]azido-cholesterol. 
Aqueous buffer was then added and the solution 
vortexed and sonicated. Greater than 98% of 
[125I]azido-cholesterol was transferred to lipid/probe 
vesicles by this process. The [125I]azido-cholesterol 
laden liposomes were combined with affinity purified 
reconstituted receptors and stirred over night at 5°C. 
- + - + - + - + 
or -V8-20-  
ct-V8-10- 
Fig. 3. Proteolytic mapping of the sites of [125I]azido-cholesterol 
incorporation i to AChR subunits using S. aureus V8 protease. 
Detergent (sodium cholate) solubilized AChRs were labeled 
with [125I]azido-cholesterol in the absence (-  lanes) or presence 
(+ lanes) of 250 p,M carbamylcholine and subjected to SDS- 
PAGE on a 1.0 mm thick 8% slab gel. AChR subunit bands 
were excised following identification by staining, transferred to 
the wells of a 15% mapping gel and overlaid with 6 gg of S. 
aureus V8 protease (see Section 2. AChR subunits were proteo- 
lytically digested as they migrated through the 4.5% acrylamide 
stacking el (50 V constant voltage, transit ime ,~ 3 h) and the 
resulting fragments were then resolved on the lower 15% acryl- 
amide separating el. Following electrophoresis, the mapping 
gel was stained with Coomassie blue R-250 and subjected to 
autoradiography (2 week exposure with intensifying screen). 
The principal [~25I]azido-cholesterol-labeled proteolytic frag- 
ments, following the nomenclature of Blanton and Cohen [26], 
are: ctV8-20 (Ser-173-Glu-338); t~V8-10 (Asn-339-Gly-437); 
[3V8-22 (Ile-173/Asn-183-Glu-383); 1]V8-12 (Met-384-Ala-469); 
(faint band) 7V8-24 (Ala-167/Trp-170-Glu-372); 7V8-14 (Leu- 
373/Ile-413-Pro-489); 7V8-12 (Ala-1 of the [3-subunit of the Tor- 
pedo Na/K-ATPase); (faint band) 8V8-20 (Ile-192-Glu-345); 
8V8-12 (Ile-192-Glu-280); 8V8-11 (Lys-436-Ala-501). 
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3.2. Mapping the sites of [leSI]azido-cholesterol 
labeling in each A ChR subunit 
Limited digestion of each AChR subunit using S. 
aureas V8 protease reproducibly generates a set of 
non-overlapping fragments [23,26]. For the AChR 
tx-subunit four principal fragments are generated 
with apparent molecular weights of 20 kDa (t~V8- 
20, Ser-173-Glu-338), 18 kDa (t~V8-18, Thr-52-Glu- 
172), 10 kDa (t~V8-10, Asn-339-Gly-437), and 4 kDa 
(t~V8-4, Ser-l-Glu-51) [23,29]. Inspection of the auto- 
radiograph of a 15% acrylamide mapping gel con- 
taining the V8 protease digests of each receptor sub- 
unit (Fig. 3) reveals that [125I]azido-cholesterol 
incorporation within the t~-subunit is restricted to 
the fragments ctV8-20 and t~V8-10. The txV8-20 
(Ser-173-Glu-338) fragment contains the hydropho- 
bic membrane spanning segments M1, M2 and M3 
while t~V8-10 (Asn-339-Gly-437) contains a large 
portion of the subunits' cytoplasmic loop as well as 
the transmembrane s gment M4. Inclusion of the 
agonist carbamylcholine does not alter the pattern 
of [125I]azido-cholesterol labeling of the ct-subunit 
which remains restricted to txV8-20 and t~V8-10 
(Fig. 3, + lane). Direct counting of excised gel bands 
shows that in the absence of agonist 26% of 
[125I]azido-cholesterol incorporation i to the t~-sub- 
unit is restricted to t~V8-20 and 74% to ~V8-10. In 
the presence of agonist, the relative incorporation is
very similiar, 20 and 80% respectively. The similarity 
in the distribution of [125I]azido-cholesterol labeling 
between the t~V8-10 and txV8-20 fragments of the 
carbamylcholine treated and untreated samples indi- 
cates that [125I]azido-cholesterol labeling is not sensi- 
tive to the conformational state of the receptor. 
Inspection of the autoradiograph of the V8 pro- 
tease digests of the ~-, 7-, and ~5-subunits (Fig. 3) 
reveals significant [125I]azido-cholesterol incorpora- 
tion into the following fragments, using the nomen- 
clature of Blanton and Cohen [26]: I]V8-22 (Ile-173/ 
Asn- 183-Glu-383); ~V8-12 (Met-384-Ala-469); (faint 
band) 7V8-24 (Ala-167/Trp-170-Glu-372); 7V8-14 
(Leu-373/Ile-413-Pro-489); 7V8-12 (Ala-1 of the ~- 
subunit of the Torpedo Na/K-ATPase); ~5V8-12 (Ile- 
192-Glu-280); ~5V8-11 (Lys-436-Ala-501). Fragments 
15V8-22 and ?V8-24 are homologous to t~VS-20 in 
that they contain the same stretch of amino acid 
residues in the aligned sequences of each subunit, 
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Fig. 4. Reverse-phase HPLC purification and sequential Edman 
degradation of a [125I]azido-cholesterol labeled fragment con- 
taining ~xM4. The [125I]azido-cholesterol-labeled 10 kDa V8 pro- 
tease fragment of the AChR cx-subunit (cW8-10, isolated from 
AChR labeled in the absence of carbamylcholine) was further 
digested in solution with trypsin and the labeled material puri- 
fied by reverse-phase HPLC (A) on a Brownlee Aquapore C4 
column (100 × 2.1 mm) as described in Section 2. The elution of 
peptides was monitored by absorbance at 210 nm (solid line) 
and elution of 125I by 7-counting of each 500 ~1 fraction (e). 
HPLC fractions 36-39 were pooled and subjected to automated 
sequential Edman degradation (B). Sixty percent of each cycle 
of Edman degradation was analyzed for released 125I (o) and 
30% for released PTH-amino acids (D) with the dashed line cor- 
responding to the exponential decay fit of the amount of de- 
tected PTH-amino acids. A primary peptide was detected begin- 
ning at Tyr-401 of the ~x-subunit (initial yield, 22 pmol; 
repetitive yield, 90.6%; 6430 cpm loaded on sequencing filter; 
1410 cpm remaining after 25 cycles). The amino acid sequence 
of the peptide is shown above B with the solid line indicating 
the limits of the M4 region. 
which includes the transmembrane s gments M1, 
M2, and M3. Similarly, [3V8-12, 7V8-14, and 6V8- 
11 are homologous to oW8-10 and contain the trans- 
membrane segment M4. 
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3.3. Mapping the sites of [125I]azido-cholesterol 
incorporation to the M4 segments of the or- 
and ),subunits and to the M1 segment of the 
ct-subunit 
The sites of [125I]azido-cholesterol labeling within 
the V8 protease subunit fragments txV8-20, t~V8-10, 
and ~/V8-14 were further defined by exhaustive pro- 
teolytic digestion with trypsin and separation of the 
digests by reverse-phase HPLC. In the HPLC chro- 
matograph of the tryptic digest of ~V8-10 (Fig. 4A) 
the vast majority of ~25I cpm elutes in a single peak 
centered in fraction 38 with a corresponding peak in 
absorbance eluting at ,-, 93 minutes. HPLC fractions 
36-39 were pooled and subjected to N-terminal ami- 
no acid sequence analysis. The major sequence de- 
tected began at ctTyr-401 (initial yield, 22 pmol; re- 
petitive yield, 90.6%). A secondary sequence was also 
present beginning at ctSer-388, 13 residues upstream 
(N-terminal) of t~Tyr-401 (initial yield, 15 pmol; re- 
petitive yield, 80%). In the 125I-release profile (Fig. 
4B) 'peptide washotF, that is removal of the 
[125I]azido-cholesterol labeled peptide from the glass 
fiber disk (see Section 2, can be seen as a cycle to 
cycle decline in the level of detected 125I cpm (6430 
cpm loaded onto sequencing filter; 1410 cpm remain- 
ing after 25 cycles). In cycle 12, there is a small, but 
significant, increase in the amount of detected 125I 
cpm which corresponds to [125I]azido-cholesterol in- 
corporation i to aCys-412 (2.3 cproJpmol) within the 
membrane-spanning se ment t~M4. Following cycle 
12, the level of 125I cpm remains elevated in cycle 13 
and this is followed by a rather a slow decline in cpm 
in cycles 14 and 15. The 125I release in cycles 13 15 
may represent [125I]azido-cholesterol incorporation 
into one or more of the residues within t~M4: 
o~Val-413, t~Phe-414, and t~Met-415. Alternatively, 
the 125I release may instead reflect the inability of 
the solvents used in automated sequencing to effi- 
ciently extract the [125I]azido-cholesterol labeled 
PTH-cysteine residue released from the peptide in 
cycle 12. No other sites of labeling are apparent 
within the ctM4 peptide. 
When the tryptic digest of ctV8-20 was separated 
by reverse-phase HPLC (Fig. 5A) the majority of 125I 
cpm elutes in a peak centered in fraction 38 with a 
corresponding peak in absorbance luting at ~ 92 
minutes. HPLC fractions 36--39 were pooled and 
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Fig. 5. Reverse-phase HPLC purification of [125I]azido-choles- 
terol labeled fragments containing ~M1 and 7M4. The 
[12SI]azido-cholesterol-labeled 20 kDa V8 protease fragment of 
the AChR a-subunit (aV8-20) and 14 kDa V8 fragment of the 
`/-subunit (7V8-14) were further digested in solution with trypsin 
and the labeled material purified by reverse-phase HPLC as de- 
scribed in Section 2 and in the legend to Fig. 4. Elution of 1251 
was determined by ,/-counting of each 500 pl fraction (I) and 
the elution of peptides by absorbance at 210 nm (solid line). 
(A) HPLC chromatograph of ~V8-20 tryptic digest; (B) HPLC 
chromatograph of ,/V8-14 tryptic digest. 
subjected to 10 cycles of automated Edman degrada- 
tion. N-Terminal sequencing identified a single se- 
quence beginning at ctIle-210 and extending into 
the membrane-spanning segment o~M1. Based on 
previous tudies establishing the point of elution of 
an ,~ 3.4 kDa tryptic fragment of oW8-20 containing 
ctM1 [26,27], the t~Ile-210 peptide extends through 
txM1 and terminates at t~Lys-242, which is at the 
amino-terminal end of the M2 segment. From the 
HPLC chromatograph of the tryptic digest of 7V8- 
14 (Fig. 5B) HPLC fractions 35-39 were pooled (125I 
cpm peak in fractions 37/38) and sequenced for 
10 cycles. Sequence analysis revealed the presence 
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of a primary sequence beginning at yVal-446. The 
7Val-446 peptide xtends through the transmembrane 
segment M4, terminating at either 7Arg-485 the next 
available tryptic cleavage site or possibly at the sub- 
unit C-terminus (Pro-489). Sequence analysis also re- 
vealed the presence of a minor secondary sequence 
beginning at ~1u-429, 17 residues upstream (N-ter- 
minal) to the start of the yVal-446 peptide and also 
presumably extending through 7M4. 
4. Discussion 
Cholesterol, an essential constituent of most eu- 
karyotic cells, is also necessary for the functional 
activity of many membrane proteins, including the 
nicotinic acetylcholine receptor [7,9,30]. While the 
requirement for cholesterol or more generally sterol 
[31] for AChR function is well established, the mech- 
anism by which cholesterol modulates the structure/ 
function of the receptor is by no means well under- 
stood. Theories of regulation based on membrane 
fluidity or bilayer structure have for the most part 
been discounted [32-34]. Cholesterol has also been 
proposed to stabilize transmembrane segment secon- 
dary structure by packing of the rigid sterol ring 
structure into grooves of transmembrane helices 
[35,36]. However in more recent structural studies 
of the AChR no significant differences in receptor 
secondary structure have been detected in the ab- 
sence of cholesterol [37]. Obtaining a better under- 
standing of the role of cholesterol in AChR struc- 
ture/function is further complicated by the lack of a 
defined binding domain for sterol. It has been pro- 
posed that there are non-annular or interstitial bind- 
ing sites for cholesterol which are distinct from the 
lipid-protein interface [16] and even extramembrane 
binding sites [15]. 
In the present study, we have employed a photo- 
reactive analog of cholesterol [3ot-(4-azido-3- 
[125I]iodosalicylic)-cholest-5-ene ([125I]azido-choles- 
terol)], to identify the binding domain for cholesterol 
in the AChR. Based upon the extremely lax struc- 
ture-activity requirements for cholesterol [31,33,34], 
[125I]azido-cholesterol serves not only as a probe on 
the cholesterol binding domain, but is probably also 
a functional substitute for cholesterol. For example, 
in reconstitution studies, cholesterol analogs derivat- 
ized at the 3' position with substituents as small as 
sulfate and as large as phosphatidylcholine, were 
shown to support AChR activity [34]. Sunshine and 
McNamee [31] reported that neutral ipids as struc- 
turally dissimiliar to cholesterol as vitamin D were 
also found to support AChR function. In addition, 
supportive vidence that azido-cholesterol is a func- 
tional substitute for cholesterol was obtained by ex- 
amining the ability of the AChR to undergo confor- 
mational transitions in the presence of the cholesterol 
probe. The pattern and extent of photoincorporation 
of 3-trifluoromethyl-3-(m[lZSI]iodophenyl) diazirine 
([125I]TID) into the AChR can be used as a diagnos- 
tic indicator of the conformational state of the 
AChR [28,29]. In the presence of 100 gM azido-cho- 
lesterol and in the absence of agonist, the pattern 
and extent of [125I]TID incorporation i to receptor 
subunits was consistent with the AChR being in the 
resting state conformation (data not shown). The 
implication of this result is that azido-cholesterol 
does not shift the conformational equilibrium of 
the AChR. In addition, as judged by the pattern of 
[~25I]TID incorporation i the presence of both ago- 
nist and azido-cholesterol, the cholesterol probe did 
not inhibit the ability of the receptor to undergo 
conformational transitions. Together, these results 
provide indirect evidence that azido-cholesterol sup- 
ports AChR activation. 
In the AChR o~-subunit, sites of [12SI]azido-choles- 
terol incorporation are restricted to the membrane- 
spanning segments o~M1 and ocM4. Previous studies 
have established that the M 1, M3, and M4 segments 
of each receptor subunit define the lipid-protein in- 
terface of the AChR [26,38,39]. The observation that 
[~25I]azido-cholesterol incorporates into the AChR 
subunits equally on a molar basis for both native 
AChR membranes and affinity purified reconstituted 
receptors indicate that the labeling is proportional to 
mass and, by implication, to the surface area exposed 
to lipid. Incorporation of [125I]azido-cholesterol into 
the ~-subunit of the Na/K-ATPase and the CLC-0 
chloride channel (Fig. 2), both multi-membrane 
spanning polypeptides, provides additional support 
that labeling is proportional to the surface area ex- 
posed to lipid. While these results support he exis- 
tence of a cholesterol binding domain at the AChR 
lipid-protein interface, they do not support he exis- 
tence of non-annular binding sites for cholesterol 
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that are distinct from the lipid-protein interface nor 
are they consistent with the presence of extramem- 
brane sterol binding sites. 
For AChRs labeled with [125I]azido-cholesterol in 
the presence and in the absence of the agonist carba- 
mylcholine, no significant differences in either the 
pattern or extent of incorporation i to AChR sub- 
units or subunit proteolytic fragments were detected. 
Similar results were observed with the cholesterol 
photoaffinity probe [3H]cholesteryl diazoacetate 
([19]; but see Fernandez et al. [20]). These data sug- 
gest that structural transitions in the receptor upon 
addition of agonist do not significantly change the 
surface area of the receptor exposed to the steroid. 
In addition, cholesterol does not appear to induce 
any significant secondary structural changes to the 
AChR transmembrane s gments [37]. Therefore, 
while the presence of cholesterol (sterol) is necessary 
for the receptor to undergo conformational transi- 
tions (reviewed in [30]), these results uggest a mech- 
anism of cholesterol modulation that involves ubtle 
changes in the structure and/or orientation of the 
lipid-exposed segments. One possibility is that cho- 
lesterol may affect the interaction/packing of trans- 
membrane segments [35] and these interactions are in 
all likelihood critical in facilitating the conformation- 
al transitions of the AChR. Localized interactions 
between the lipid-exposed segments M4, M3, and 
M1 and the channel-lining M2 segment are clearly 
important in mediating the agonist-induced transi- 
tions necessary for channel opening [40,41]. Substi- 
tution of lipid-exposed residues [42] as well as the 
interaction of agents with the lipid-protein interface 
[43,44] also appear to modulate these interactions as 
judged by effects on AChR channel properties. Cho- 
lesterol does not appear to act by altering the sec- 
ondary structure of the membrane-spanning se - 
ments in any significant fashion [37], but may 
instead act as a sort of 'molecular grease' in facilitat- 
ing subtle structural movements of the transmem- 
brane segments that occur during conformational 
transitions. A sterol binding site at the interfaces of 
membrane-spanning se ments [45] is consistent with 
the results of Dreger et al. [15]. In this study, it was 
found that proteolytic removal of the extramem- 
brane portions of the AChR resulted in a loss of 
receptor-specific binding sites for the spin-labeled 
sterol adrostane. The authors interpreted these re- 
suits as suggesting the existence of extramembrane 
sterol binding sites. An alternative xplanation is 
that extramembrane regions and in particular the 
loops connecting the transmembrane s gments are 
critically important in stabilizing the interaction/ 
packing of membrane-spanning se ments. Removal 
of the loops connecting the transmembrane segments 
would serve to destabilize their packing and result in 
a disruption of cholesterol binding sites. Along these 
lines, future cross-linking studies with analogs of 
cholesterol may be useful in further defining the 
sterol binding domain as well as the structure of 
the AChR transmembrane domain. 
In summary, this study represents an important 
step in elucidating the molecular details of the cho- 
lesterol-AChR interaction. Sites of incorporation of 
the photoactivatable cholesterol analog [~25I]azido- 
cholesterol were localized to transmembrane s g- 
ments which form the lipid-protein interface of the 
AChR. Additional work will be necessary to identify 
specific amino acid residues in each lipid-exposed 
transmembrane segment which interact with choles- 
terol. Nonetheless, these results support a possible 
mechanism for the requirement of cholesterol for 
AChR function that involves sterol facilitating the 
packing/interaction of membrane-spanning a-helical 
segments. 
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